“Clear effect if administered within 7 days”
Obtained EMA·FDA emergency use approval by July this year
viewer
Celltrion (068270)Prior to the release of the results of phase 2 clinical trials for the novel coronavirus infection (Corona 19) antibody treatment’Rekyrona’, it was mentioned that it had confirmed the effect equal to or higher than those of Eli Lilly and Regeneron antibody treatments approved for emergency use in the United States. Celltrion will unveil the specific results of Phase 2 clinical trials on Rekkirona at the High1 New Drug Development Symposium hosted by the Korean Pharmaceutical Association on the 13th.
Celltrion R&D Headquarters Kwon Ki-sung said, “The target group was similar to (Lily, Regeneron Antibody Treatment)” at the discussion on’Communication with the Future: The Road to the Corona Clean Country’ held by Democratic Party lawmaker Lee Gwang-jae of the National Assembly Planning and Finance Committee on the 12th. “We got equal or higher results up to severe,” he said. “When inflammation in the lungs develops, the amount of virus is not high, so if you administer it as soon as possible, within 7 days, there is a definite effect.”
Celltrion plans to obtain Rekkirona’s emergency use approval from the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) by July this year. General Manager Kwon said, “It is difficult to go overseas because Lily and Regeneron are not enough to be used in the United States,” he said. “When the results of phase 2 clinical trials (Celltrion Antibody Therapy) are opened, overseas exports will be actively progressing. We are discussing with the state.” On this day, Jae-woo Lee, head of development headquarters of GC Green Cross, and Hyun-jin Park, head of development headquarters of Daewoong Pharmaceutical (069620), also participated in the discussion to share the development of COVID-19 treatment.
/ Reporter Woo Young-tak [email protected]
< 저작권자 ⓒ 서울경제, 무단 전재 및 재배포 금지 >